On June 4, Ali Health fell 3.01% in regular trading, trading at HK$3.55/share, with trading volume of HK$189 million, extending its post-earnings weakness.

On the news front, the company's previously reported FY26 results showed second-half revenue growth of only 7.6%, significantly below the market consensus of 13.8%. Following the results, UBS, Goldman Sachs, CLSA, and Bank of America collectively cut target prices and earnings forecasts, with UBS maintaining a Sell rating and lowering its target to HK$3.6. Meanwhile, the newly issued prescription drug online retail compliance guidelines — banning AI-based prescription review and restricting prescription drug promotions — are expected to raise platform compliance costs and pressure near-term profitability for online pharmaceutical platforms.

Sector-wide weakness reinforced the decline, with JD Health down 2.15%, PA Good Doctor down 1.99%, and Meituan down 2.86%, reflecting broad selling pressure across the Internet and Direct Marketing Retail sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)